Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 18;11(3):293.
doi: 10.3390/healthcare11030293.

Development of Clinical Prediction Score for Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients

Chawalit Chayangsu  1 , Jiraporn Khorana  2   3 , Chaiyut Charoentum  4 , Virote Sriuranpong  5 , Jayanton Patumanond  3 , Apichat Tantraworasin  3   6
Affiliations

Development of Clinical Prediction Score for Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients

Chawalit Chayangsu et al. Healthcare (Basel). .

Abstract

The outcomes of advanced non-small cell lung cancer (NSCLC) patients have been significantly improved with novel therapies, such as tyrosine kinase inhibitors and immune checkpoint inhibitors. However, in resource-limited countries, platinum-doublet chemotherapy is mainly used as a first-line treatment. We investigate clinical parameters to predict the response after chemotherapy, which may be useful for patient selection. A clinical prediction score (CPS) was developed, based on data from a retrospective cohort study of unresectable stage IIIB or IV NSCLC patients who were treated with platinum-doublet chemotherapy in the first-line setting with at least two cycles and an evaluated response by RECIST 1.1 at Surin Hospital Cancer Center, Thailand, between July 2014 and December 2018. The clinical parameters in the prediction model were derived by risk regression analysis. There were 117 responders (CR or PR) and 90 non-responders (SD or PD). The clinical prediction score was developed by six clinical parameters including gender, age, smoking status, ECOG, pre-treatment albumin, and histologic subtype. The AuROC of the model was 0.71 (95% CI 0.63-0.78). The internal validation was performed using a bootstrap technique and showed a consistent AuROC of 0.66 (95% CI 0.59-0.72). The prediction score ranged from 0-13, with a score of 0-8 meaning a low probability (PPV = 50%) and a score of 8.5-13 meaning a high probability (PPV = 83.7%) for chemotherapy response. Advanced NSCLC patients who cannot access novel therapies and have a CPS of 8.5-13 have a high probability for chemotherapy response in the first-line setting. This CPS could be used for risk communication and making decisions with patients, especially in regard to chemotherapy.

Keywords: advanced lung cancer; chemotherapy; clinical prediction rule; decision making; limited resources.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study flow diagram.
Figure 2
Figure 2
Performance of the clinical prediction score, area under the receiver operating characteristics (ROC) curve.
Figure 3
Figure 3
Observed risk (circle) versus score-predicted risk (solid line) of responder probability.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Mithoowani H., Febbraro M. Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology. Curr. Oncol. 2022;29:1828–1839. doi: 10.3390/curroncol29030150. - DOI - PMC - PubMed
    1. Zhang C., Leighl N.B., Wu Y.-L., Zhong W.-Z. Emerging Therapies for Non-Small Cell Lung Cancer. J. Hematol. Oncol. 2019;12:45. doi: 10.1186/s13045-019-0731-8. - DOI - PMC - PubMed
    1. Eaton K.D., Jagels B., Martins R.G. Value-Based Care in Lung Cancer. Oncologist. 2016;21:903–906. doi: 10.1634/theoncologist.2016-0116. - DOI - PMC - PubMed
    1. Permsuwan U., Niamhun N., Tanatip N., Thongprasert S. Epidermal Growth Factor Receptor Mutation Testing in Thailand: A Cost-Utility Analysis. Value Health Reg. Issues. 2014;3:39–43. doi: 10.1016/j.vhri.2013.12.001. - DOI - PubMed